Post “As an investor we’re often thinking about how to guide the company to a particular exit scenario”
Post Karin Conde-Knape, Senior Vice President of Global Drug Discovery at Novo Nordisk, about NLSDays Grand Opening
Post Mike Ryan, Executive Vice President, Europe, Eversana about NLSDays’ Vaccine Crosslinks: From Cancer to COVID super session
Post Michael Engsig, CEO, Nykode Therapeutics about NLSDays’ Vaccine Crosslinks: From Cancer to COVID super session
Post Dr. Richard Stratford, the CEO of NEC Oncoimmunity about NLSDays’ Vaccine Crosslinks: From Cancer to COVID super session
Post Dr. Carl Kilander, Partner, Healthcapabout NLSDays’ Vaccine Crosslinks: From Cancer to COVID super session
Post Dr. Gunnveig Grødeland, Research Group Lead, Influenza and Adaptive Immunity, Institute for Clinical Medicine, University of Oslo
Post Dr. Holger Kissel Vice President Business Alliances at BioNTechabout NLSDays’ Vaccine Crosslinks: From Cancer to COVID super session
